Technical Data
P4256-31B
Plasminogen Activator Inhibitor Type 1, inhibitory (PAI-1)
Description:
Plasminogen Activator Inhibitor 1 (PAI-1) is a glycoprotein found in plasma that is implicated in the processes of angoigenisis, hemostasis, tumor metastasis, fibrionlysis, ovulation, embryonic development and inflammation. The elevation of PAI-1 has shown to correlate with the prognosis of many cancers including breast cancer. PAI-1 is activated by the glycoprotein vitronectin. Vitronectin binds to PAI-1 and modulates fibrinolysis and cell migration. This binding has proven to be an important inhibitor of the activated form of protein C (APC).

Applications:
Suitable for use in Western Blot, Immunohistochemistry and ELISA. Other applilcations have not been tested.

Recommended Dilutions:
Optimal dilutions to be determined by the researcher.

Moleular Weight:
Non-glycosylated PAI-1: 43kD
Glycosylated PAI-1: 50kD

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG16F220Affinity Purified
SizeStorageShippingSourceHost
500ug-20CBlue IceHumanMouse
Concentration:
~3mg/ml
Immunogen:
Recombinant human PAI-1.
Purity:
Purified by Protein A affinity chromatography.
Form
Supplied in liquid in PBS, pH 7.4.
Specificity:
Recognizes human PAI-1 and exhibits inhibitory characteristics. Binds to an epitope localized to the F-Helix of PAI-1. The PAI-1/mab complex acts as a substrate for its target proteinases tPA and uPA. Species Crossreactivity: mouse.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Debrock, S., Declerck, P.J., Neutralization of plasminogen activator inhibitor-1 inhibitory properties: Identification of two distinct mechanisms. Biochim Biophys Acta 1337: 257-266 (1997). 2. Debrock, S., Declerck, P.J., Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop. Thromb. Haemostas. 79: 597-601 (1998). 3. Bijnens, A.P., Gils, A., Knockaert, I., Stassen, J.M., Declerck, P.J., Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. J. Biol. Chem. 275(9): 6375-80 (2000, Mar 3). 4. Ngo, T.H., Hoylaerts, M.F., Knockaert, I., Brouwers, E., Declerck, P.J., Identification of a target-site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitory properties concomitant with an allosteric upregulation of its anti-adhesive properties. J. Biol. Chem. (2001, May 7).
General references: 1. Sherman, P.M., et al., J. Biol. Chem. 267: 7588-7595 (1992). 2. McMahon, G.A., et al., J. Biol. Chem. 276: 33964-33968 (2001). 3. Devy, L., et al., FASEB J. 16: 147-154 (2002). 4. Schneider, J., et al., Brit. J. Canc. 88(1): 96-10 (2003). 5. Hou, A., et al., 10(7): 541-544 (2003). 6. Rezaie, R., et al., J. Biol. Chem. 276: 15567-15570 (2001). 7. Stegansson, S., et al., J. Biol. Chem. 273: 6358-6366 (1998).